CCHF is a serious viral disease with no approved vaccines or treatments. A new mouse study in npj Vaccines, led by a team that includes Scott Pegan at UC Riverside, tested an experimental vaccine. The vaccine uses a harmless virus-like replicon particle that can enter cells but cannot replicate because it lacks the virus genetic material.
The team had shown earlier that one dose could protect animals within three days. In the new work researchers measured antibodies after one or two doses. Antibodies remained detectable for up to 18 months, roughly like several years in humans. A booster produced stronger, more stable antibodies and longer protection. Next steps include large-scale production under Good Manufacturing Practice before human trials, and partners at the CDC are exploring the same platform for other viruses.
Difficult words
- experimental — not fully tested; a new treatment in tests
- replicon — a small virus-like particle used in research
- replicate — to make a copy of itself
- antibody — a blood protein that fights infectionAntibodies
- booster — an extra dose of a vaccine
- detectable — can be found or measured
- protection — the state of being safe from disease
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Do you think it is important to test vaccines in animals before people? Why?
- Would you take a booster if it gave longer protection? Why or why not?
- What information would you want before human trials begin?
Related articles
New inflammatory pathway may explain some rheumatoid arthritis treatment failures
A Washington State University study found that a lesser-known TWEAK–Fn14 pathway can join with TNF to increase inflammation. Blocking Fn14 reduced this surge and may explain why some patients do not respond to TNF inhibitors.
Personalized DNA vaccine shows promise against glioblastoma
A phase 1 trial found the personalized DNA vaccine GNOS-PV01 is safe and shows early signs of activity against glioblastoma. The small study at Siteman Cancer Center and WashU Medicine reported immune responses and encouraging clinical outcomes.
Depression test works for people with chronic pain
Researchers found that a common eight-question depression test gives similar results for people with and without chronic pain. The study used a large 2019 US health survey and says clinicians can trust positive screens in patients with pain.
